J. Crawford

J. Crawford, M. Dinan, S. Ramalingam, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Small-cell lung cancer: a review of clinical trials.

J. Crawford, R. Riedel, 2003, Seminars in thoracic and cardiovascular surgery.

Phase II Multicenter Trial of Voreloxin as Second-Line Therapy in Chemotherapy-Sensitive or Refractory Small Cell Lung Cancer

D. Ettinger, J. Temel, G. Shapiro, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.

R. Govindan, D. Carbone, P. Fidias, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting Anemia in Patients with Lung Cancer

F. Hirsch, J. Crawford, C. Langer, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Cost Effectiveness, Quality-Adjusted Life-Years and Supportive Care

E. Berndt, J. Crawford, S. Finkelstein, 1999, PharmacoEconomics.

Impact of correction of anemia on clinical outcome in patients with cancer: recent data from head and neck and breast cancer trials.

J. Crawford, V. Jain, A. Gibson, 2004, Supportive cancer therapy.

Brief Report: SWOG S1400B (NCT02785913), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).

R. Herbst, J. Bradley, K. Kelly, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study

G. Lyman, J. Crawford, D. Dale, 2015, SpringerPlus.

Risk assessment and guidelines for first-cycle colony-stimulating factor use in the management of chemotherapy-induced neutropenia.

J. Crawford, 2006, Oncology.

Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy.

J. Griggs, G. Lyman, J. Crawford, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preventing Obesity and Its Consequences: Highlights of RAND Health Research

Arleen F. Brown, Ariane L. Bedimo-Rung, P. Shekelle, 2011 .

Sarcopenia: A Time for Action. An SCWD Position Paper

L. Ferrucci, S. Heymsfield, S. Anker, 2019, Journal of cachexia, sarcopenia and muscle.

Neutropenia and Its Complications

G. Lyman, J. Crawford, D. Dale, 2008 .

Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer.

G. Lyman, A. Secord, J. Crawford, 2013, Gynecologic oncology.

Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: a preliminary report of a phase I dose escalation trial from the Carolina Conformal Therapy Consortium.

M. Socinski, S. Zhou, M. Anscher, 2001, The oncologist.

Myeloid Growth FactorsPractice Guidelines in Oncology

J. Armitage, G. Lyman, P. Westervelt, 2011 .

NCCN Myeloid Growth Factors Clinical Practice Guidelines in Oncology

J. Armitage, G. Lyman, P. Westervelt, 2011 .

Myeloid growth factors clinical practice guidelines in oncology.

J. Armitage, G. Demetri, G. Lyman, 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

Changing patterns of chemotherapy relative dose intensity and supportive care for aggressive B-cell non-Hodgkin lymphoma

G. Lyman, J. Crawford, D. Dale, 2016, Leukemia & lymphoma.

Sunitinib (S) switch maintenance in advanced non-small cell lung cancer (NSCLC): An ALLIANCE (CALGB 30607), randomized, placebo-controlled phase III trial.

M. Socinski, M. Edelman, E. Vokes, 2014 .

Switch Maintenance With Sunitinib (S) in Advanced Non-Small Cell Lung Cancer (NSCLC): An Alliance (CALGB 30607), Randomized, Placebo-Controlled Phase 3 Trial

M. Socinski, M. Edelman, E. Vokes, 2014 .

An analysis of the prevalence of HER2 and KRAS mutations, and ALK rearrangements and clinical outcomes in Cancer and Leukemia Group B [CALGB (Alliance)] trial 30406 in advanced non-small cell lung cancer (NSCLC).

P. Jänne, M. Socinski, V. Miller, 2013 .

Molecular Mechanisms Involved in the Immune Control of the Malignant Disease Process

J. Crawford, G. Coppa, E. Molmenti, 2017 .

Stem cell factor is a potent synergistic factor in hematopoiesis.

G. Demetri, J. Crawford, M. Gordon, 1994, Oncology.

Safety and Efficacy of Pegfilgrastim in Patients Receiving Myelosuppressive Chemotherapy

J. Crawford, 2003, Pharmacotherapy.

Do Patients Regret Having Received Systemic Treatment for Advanced Non-Small Cell Lung Cancer: A Prospective Evaluation.

G. Weiss, B. Halmos, J. Crawford, 2020, The oncologist.

Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.

Thomas J. Smith, J. Armitage, A. Wozniak, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Adenocarcinoma of the Gastroesophageal Junction: Preoperative Cisplatin and Concomitant Continuous Infusion 5-Fluorouracil and Radiation Therapy

J. Crawford, I. Crocker, L. Prosnitz, 1991 .

A combined analysis of average relative dose intensity in the chemotherapy of solid tumors with pegfilgrastim or filgrastim support.

J. Crawford, S. Shahin, Michael Green, 2005, Supportive cancer therapy.

Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia.

J. Crawford, J. Glaspy, M. Vincent, 2005, Supportive cancer therapy.

Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia.

J. Crawford, 2003, Seminars in oncology.

Disorders of Blood Cell Production in Clinical Oncology

J. Crawford, J. Choe, 2020 .

Immune Checkpoint Inhibition

J. Crawford, A. Salama, S. Sammons, 2018 .

Reduction of oral mucositis by filgrastim (r-metHuG-CSF) in patients receiving chemotherapy.

J. Crawford, J. Glaspy, H. Ozer, 1999, Cytokines, cellular & molecular therapy.

A Randomized Trial Comparing Immediate versus Delayed Treatment of Anemia with Once-Weekly Epoetin Alfa in Patients with Non-small Cell Lung Cancer Scheduled to Receive First-Line Chemotherapy

J. Crawford, M. Perry, C. Belani, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

796 Prevention of chemotherapy related anemia by recombinant human erythropoietin (EPO) in patients with small cell lung cancer (SCLC) receiving cyclophosphamide, doxorubicin, and etoposide (CAE) chemotherapy with G-SCF support

E. Winer, J. Herndon, J. Crawford, 1997 .

Clinical benefits of epoetin alfa therapy in patients with lung cancer.

G. Demetri, J. Gabrilove, J. Crawford, 2002, Clinical lung cancer.

Request for regulatory guidance for cancer cachexia intervention trials

L. Ferrucci, M. Polkey, K. Kalantar-Zadeh, 2015, Journal of cachexia, sarcopenia and muscle.

Hematopoietic growth factors in the reduction of chemotherapeutic toxicity.

J. Crawford, Johnston Em, E. Johnston, 1998, Seminars in oncology.

A phase II multicycle trial of pegfilgrastim compared to Filgrastim after myelosuppressive chemotherapy

J. Crawford, J. Garst, C. Belani, 2000 .

O-254 Prevention of anemia with once weekly (QW) epoetin alfa in patients with non-small-cell lung cancer (NSCLC)

J. Crawford, M. Perry, C. Belani, 2003 .

Economic analysis of pegfilgrastim in patients receiving cancer chemotherapy

G. Lyman, J. Crawford, L. Cosler, 2005 .

Pegfilgrastim Administered Once Per Cycle Reduces Incidence of Chemotherapy-Induced Neutropenia

J. Crawford, 2002, Drugs.

Reply to N. Lathia et al

G. Lyman, J. Crawford, D. Dale, 2010 .

Hematopoietic growth factors: ESMO recommendations for the applications.

R. Greil, J. Crawford, F. Roila, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies

J. Crawford, N. Gabrail, J. Goldschmidt, 2015, Supportive Care in Cancer.

Vinorelbine and Carboplatin in the Treatment of Advanced Non-Small-Cell Lung Cancer

J. Crawford, M. O'Rourke, J. Garst, 2017 .

Docetaxel/Vinorelbine Combination Therapy in Non-Small-Cell Lung Cancer

J. Crawford, 1997 .

A phase II study of GDC-0032 (taselisib) for previously treated PI3K positive patients with stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400B.

R. Herbst, J. Bradley, K. Kelly, 2017 .

Advances in the Management of Chemotherapy-Induced Neutropenia

J. Crawford, 2006 .

Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.

G. Lyman, V. Sivasubramaniam, J. Crawford, 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Reduced Relative Dose Intensity (RDI) in Patients with Aggressive Non-Hodgkin’s Lymphoma (NHL).

G. Lyman, J. Crawford, D. Dale, 2004 .

Risk of neutropenic complications based on a prospective nationwide registry of cancer patients initiating systematic chemotherapy

G. Lyman, J. Crawford, M. Poniewierski, 2004 .

Predicting the risk of neutropenic complications and reduced dose intensity in patients with early-stage breast cancer (ESBC): Results from a prospective nationwide registry.

G. Lyman, J. Crawford, E. Culakova, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy.

H. Garewal, J. Crawford, S. Jones, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

The Role of Plerixafor (AMD3100) in Mobilizing Hematopoietic Progenitor Cells in Patients with Hematologic Malignancies.

J. Crawford, G. Reddy, V. Jain, 2006, Supportive cancer therapy.

1120 POSTER Evaluation of the association between hemoglobin (Hb) events and safety outcomes in cancer patients (pts) with chemotherapy-induced anemia (CIA): an integrated analysis of patient-level data from 6 randomized, placebo-controlled trials (RCTs) of darbepoetin alfa (DA)

J. Crawford, H. Ludwig, J. Glaspy, 2007 .

Developments in Molecular Testing and Biosimilars.

R. Carlson, J. Crawford, K. Winckworth-Prejsnar, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices

J. Crawford, D. Dale, R. Rifkin, 2022, Supportive Care in Cancer.

Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer

G. Lyman, P. Fox, D. Patt, 2018, Clinical breast cancer.

Use of hematopoietic growth factors in the management of infection in oncology patients

J. Crawford, D. Mcgaughey, 2003 .

The Impact of Therapy (Recombinant Granulocyte

J. Crawford, J. Glaspy, R. Stoller, 1993 .

The role of colony stimulating factors as an adjunct to lung cancer chemotherapy: A commentary

J. Crawford, Mark R. Green, 1992 .

Initial cohort toxicity evaluation for chemoradiotherapy (CRT) and ZD1839 in stage III non-small cell lung cancer (NSCLC): A CALGB stratified phase II trial

Michael R. Green, J. Herndon, E. Vokes, 2004 .

Use of prophylactic pegfilgrastim for chemotherapy-induced neutropenia in the US: A review of adherence to present guidelines for usage.

J. Crawford, V. Morrison, D. Dale, 2021, Cancer treatment and research communications.

Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer

G. Lyman, D. Patt, J. Crawford, 2019, Supportive Care in Cancer.

Randomized, D ose-Escalation S tudy o f S D/01 C ompared With D aily F ilgrastim i n P atients R eceiving C hemotherapy

J. Crawford, J. Garst, L. Roskos, 2000 .

Vinorelbine (Navelbine)/carboplatin combination therapy: dose intensification with granulocyte colony-stimulating factor.

J. Crawford, M. O'Rourke, 1994, Seminars in oncology.

Anemia and lung cancer.

J. Crawford, 2002, Lung cancer.

Recombinant Human Erythropoietin in Cancer-Related Anemia

J. Crawford, 2002 .

Colony-stimulating factor use in the context of refined risk and benefit assessments.

J. Crawford, 2006, Oncology.

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Thomas J. Smith, Gary H Lyman, Thomas J Smith, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prevention and treatment of chemotherapy-induced neutropenia.

J. Crawford, 2013, Clinical advances in hematology & oncology : H&O.

Complications and costs associated with febrile neutropenia in hospitalized adult cancer patients

G. Lyman, J. Crawford, D. Dale, 2004 .

Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis

Ying Cheng, M. Ahn, T. Mok, 2020 .

Prospective validation of a risk model for first cycle neutropenic complications in patients receiving cancer chemotherapy.

G. Lyman, J. Crawford, N. Kuderer, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Meta-analysis of prophylactic granulocyte colony-stimulating factor (G-CSF) in cancer patients receiving chemotherapy

G. Lyman, J. Crawford, D. Dale, 2005 .

Formation of a bronchoesophageal fistula following concurrent radiation and chemotherapy for lung cancer in the setting of Behçet's disease.

M. Wahidi, J. Crawford, C. Kelsey, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?

M. Aapro, J. Crawford, J. Glaspy, 2022, The oncologist.

Impact of the multinational association of supportive care in cancer on supportive cancer therapy.

J. Crawford, 2005, Supportive cancer therapy.

Colony‐Stimulating Factors: Clinical Applications

J. Crawford, S. Blackwell, 1992, Pharmacotherapy.

Recombinant human erythropoietin in cancer-related anemia. Review of clinical evidence.

J. Crawford, 2002, Oncology.

Myeloid growth factors. Clinical practice guidelines in oncology.

J. Armitage, G. Demetri, G. Lyman, 2007, The Journal of the National Comprehensive Cancer Network.

Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.

G. Lyman, J. Crawford, D. Dale, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel.

J. Armitage, James R. Anderson, M. Somerfield, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of fungal infections in cancer patients

G. Lyman, J. Crawford, J. Klastersky, 2008 .

The Nature and Function of Immunogenic Tumor Proteins That Characterize Pancreatic and Colorectal Cancer: A Review

J. Crawford, G. Coppa, E. Molmenti, 2015 .

Human recombinant stem-cell factor induces melanocytic hyperplasia in susceptible patients.

J. Grichnik, J. Kurtzberg, J. Crawford, 1995, Journal of the American Academy of Dermatology.

Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the lung cancer symptom scale

M. Kris, J. Crawford, R. Gralla, 1994, Cancer.

Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.

Edward J. Lee, M. Caligiuri, C. Bloomfield, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Small-cell lung cancer: prognostic factors and changing treatment over 15 years.

R. Herbst, L. Gaspar, J. Crawford, 2012, Clinical lung cancer.

Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens.

J. Griggs, G. Lyman, J. Crawford, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation.

R. Clough, M. Anscher, J. Herndon, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular landscape of BRAF-mutant NSCLC reveals an association between clonality and driver mutations and identifies targetable non-V600 driver mutations.

D. Gandara, F. Meric-Bernstam, J. Crawford, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

ACP Medicine

J. Crawford, 2004 .

Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.

M. Kris, W. Gradishar, G. Lyman, 1994, The New England journal of medicine.

Highlights from: The 46th Annual Meeting of the American Society of Hematology; San Diego, CA.

J. Crawford, G. Reddy, V. Jain, 2005, Supportive cancer therapy.

Activation of tyrosine kinases in cancer.

J. Crawford, G. Vlahović, 2003, The oncologist.

Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer.

R. Figlin, J. Crawford, L. Harker, 1997, The New England journal of medicine.

Cancer supportive care : advances in therapeutic strategies

G. Lyman, J. Crawford, 2008 .

The importance of chemotherapy dose intensity in lung cancer.

J. Crawford, 2004, Seminars in oncology.

Consensus on medical treatment of non-small cell lung cancer.

Christina J. Herold, C. Gridelli, F. Hirsch, 2002, Lung cancer.

Deferasirox (ICL670; Exjade(R)), a Novel Orally Available Iron Chelator for Correction of Transfusion-Associated Iron Overload.

J. Crawford, V. Jain, P. Tyagi, 2005, Supportive cancer therapy.

Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

J. Armitage, H. Rugo, G. Lyman, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

RNA splicing and aggregate gene expression differences in lung squamous cell carcinoma between patients of West African and European ancestry.

H. Dressman, K. Owzar, R. Kittles, 2021, Lung cancer.

Preoperative radiation therapy and chemotherapy for pulmonary blastoma: a case report.

J. Crawford, T. D’amico, C. Kelsey, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Risk of neutropenic complications based on a prospective nationwide registry of cancer patients initiating systematic chemotherapy.

G. Lyman, J. Crawford, M. Poniewierski, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy.

J. Crawford, J. Garst, J. Crawford, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carboplatin/Paclitaxel or Carboplatin/Vinorelbine Followed by Accelerated Hyperfractionated Conformal Radiation Therapy: Report of a Prospective Phase I Dose Escalation Trial From the Carolina Conformal Therapy Consortium

M. Socinski, R. Clough, M. Anscher, 2004 .

Small cell lung cancer clinical practice guidelines in oncology.

D. Ettinger, J. Crawford, F. Fossella, 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?

M. Aapro, J. Crawford, D. Kamioner, 2010, Supportive Care in Cancer.

O-082 A randomized phase III trial comparing ionafarnib/carboplatin/paclitaxel versus carboplatin/paclitaxel (CP) in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC)

F. Khuri, A. Santoro, J. Crawford, 2005 .

Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy

G. Lyman, J. Crawford, D. Dale, 2011, Cancer.

Myeloid growth factors.

J. Armitage, M. Dwyer, H. Rugo, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Clinical uses of pegylated pharmaceuticals in oncology.

J. Crawford, 2002, Cancer treatment reviews.

Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab

M. Berry, D. Harpole, S. McCall, 2017, Clinical Cancer Research.

A Phase II Trial of Carboplatin/Vinorelbine with Pegfilgrastim Support for the Treatment of Patients with Advanced Non-small Cell Lung Cancer

J. Herndon, J. Crawford, R. Riedel, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Predictors of Physical and Functional Loss in Advanced‐Stage Lung Cancer Patients Receiving Platinum Chemotherapy

J. Crawford, E. Kinsey, Xiaofei Wang, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety and pharmacokinetics (PK) of AMG 706 in combination with panitumumab and gemcitabine-cisplatin in patients (pts) with advanced cancer

J. Crawford, H. Burris, G. Otterson, 2007 .

Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105).

Narasimhan P. Agaram, R. Maki, G. Schwartz, 2018 .

Overcoming obstacles in the design of cancer anorexia/weight loss trials.

J. Crawford, W. Evans, A. Jatoi, 2017, Critical reviews in oncology/hematology.

P-460 Results of a phase 2 trial of HGS-ETR1 (agonistic humanmonoclonal antibody to TRAIL receptor 1) in subjects with relapsedlrecurrent non-small cell lung cancer (NSCLC)

K. Kelly, J. Crawford, Y. Oh, 2005 .

Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.

K. Kelly, J. Crawford, Y. Oh, 2008, Lung cancer.

Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer.

J. Crawford, D. Yoo, C. Kelsey, 2016, Lung cancer.

Stem Cell Factor

G. Demetri, G. Tricot, C. Begley, 2000 .

Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies

R. Figlin, A. Belldegrun, A. Tolcher, 2008, Clinical Cancer Research.

Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer.

R. Clough, L. Marks, J. Crawford, 2003, International journal of radiation oncology, biology, physics.

Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review.

G. Lyman, J. Crawford, D. Dale, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury.

M. Dewhirst, R. Clough, M. Anscher, 2006, International journal of radiation oncology, biology, physics.

Therapeutic Use of Granulocyte Colony-Stimulating Factors for Established Febrile Neutropenia

G. Lyman, J. Crawford, L. Cosler, 2012, PharmacoEconomics.

Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.

J. Friedberg, R. Fisher, G. Lyman, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer.

J. Crawford, R. Buller, J. Garst, 2005, Clinical lung cancer.

A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis

J. Crawford, D. Dale, R. Rifkin, 2022, Supportive Care in Cancer.

Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety

J. Crawford, Sinéad M. Flannery, R. Mahtani, 2021, BMC Cancer.

Crawford J, Dale DC, Lyman GH. Chemotherapy‐induced neutropenia: risks, consequences, and new directions for its management. Cancer. (2004) 100(2):228–37.

G. Lyman, J. Crawford, D. Dale, 2004 .

Improving clinical practice: the importance of guideline development.

J. Crawford, 2005, Supportive cancer therapy.

Myeloid growth factors.

J. Armitage, G. Demetri, G. Lyman, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

Analysis of Factors Associated With In‐hospital Mortality in Lung Cancer Chemotherapy Patients With Neutropenia

G. Lyman, J. Crawford, D. Dale, 2017, Clinical lung cancer.

A Phase 2 Randomized Trial of Paclitaxel and Carboplatin with or without Panitumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Daniel J. Freeman, J. Crawford, D. Prager, 2013, Journal of Thoracic Oncology.

Highlights from: The 41st Annual Meeting of the American Society of Clinical Oncology; Orlando, FL.

J. Crawford, G. Reddy, V. Jain, 2005, Supportive cancer therapy.

The lung cancer exercise training study: a randomized trial of aerobic training, resistance training, or both in postsurgical lung cancer patients: rationale and design

W. Kraus, P. Douglas, A. Potti, 2010, BMC Cancer.

Safety and feasibility of aerobic training on cardiopulmonary function and quality of life in postsurgical nonsmall cell lung cancer patients

W. Kraus, P. Douglas, D. Harpole, 2008, Cancer.

Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy

G. Lyman, J. Crawford, D. Dale, 2005, Cancer.

Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors.

S. Loibl, J. Crawford, A. Chan, 2012, Critical reviews in oncology/hematology.

A Pooled Analysis of Limited-Stage Small-Cell Lung Cancer Patients Treated with Induction Chemotherapy Followed by Concurrent Platinum-Based Chemotherapy and 70 Gy Daily Radiotherapy: CALGB 30904

E. Vokes, J. Crawford, H. Pang, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Limited-stage small-cell lung cancer (stages I-III): observations from the National Cancer Data Base.

R. Herbst, L. Gaspar, J. Crawford, 2005, Clinical lung cancer.

What are the criteria for response to cachexia treatment?

J. Crawford, 2019, Annals of palliative medicine.

A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia.

P. Gascón, J. Crawford, F. Scotté, 2018, Critical reviews in oncology/hematology.

Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials)

J. Crawford, R. Gralla, J. Dalton, 2016, Current Oncology Reports.

Enobosarm and lean body mass in patients with non-small cell lung cancer.

J. Crawford, J. Dalton, M. Steiner, 2014 .

Hematopoietic growth factors.

J. Crawford, 2003, Hematology/oncology clinics of North America.

Comprehensive symptom management in advanced lung cancer: E10-05

J. Crawford, 2007 .

A Phase I Study of Dose-Dense Topotecan Given Upfront to Standard Therapy in Patients with Small Cell Lung Cancer

J. Herndon, J. Crawford, J. Garst, 2006, Clinical drug investigation.

Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive‐Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE)

E. Vokes, J. Crawford, H. Pang, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Osimertinib for patients with leptomeningeal metastases associated with epidermal growth factor receptor T790M positive advanced NSCLC: the AURA LM analysis.

Ying Cheng, M. Ahn, T. Mok, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting

G. Lyman, J. Crawford, D. Dale, 2013, Breast Cancer Research and Treatment.

Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy

G. Lyman, J. Crawford, D. Dale, 2009, Cancer.

Accuracy of positron emission tomography in identifying hilar (N1) lymph node involvement in non-small cell lung cancer: Implications for stereotactic body radiation therapy.

R. Coleman, M. Berry, L. Marks, 2015, Practical radiation oncology.

Neutrophil growth factors.

J. Crawford, 2002, Current hematology reports.

Long-term complication risk after very high dose thoracic radiotherapy

R. Clough, M. Anscher, J. Herndon, 2002 .

Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: Results from an Online Survey of Patients with Solid Tumors

R. Epstein, M. Aapro, J. Crawford, 2020, Advances in Therapy.

A risk model for first cycle febrile neutropenia in cancer patients receiving systemic chemotherapy

G. Lyman, J. Crawford, D. Dale, 2005 .

Clinical results in cachexia therapeutics

J. Crawford, 2016, Current opinion in clinical nutrition and metabolic care.

Impact of Comorbidities on Length of Stay and Mortality in Hospitalized Patients with Cancer and Febrile Neutropenia

G. Lyman, J. Crawford, D. Dale, 2014 .

P5-20-03: Personalizing Supportive Care: A Clinical Prediction Model for Neutropenic Complications in Patients with Early-Stage Breast Cancer (ESBC) Receiving Intermediate Risk Chemotherapy.

G. Lyman, J. Crawford, N. Kuderer, 2011 .

Personalizing Cancer Supportive Care: Predicting Neutropenic Complications in Patients Receiving Intermediate Risk Cancer Chemotherapy

G. Lyman, J. Crawford, D. Dale, 2011 .

Cancer cachexia: Are we ready to take a step forward?

J. Crawford, 2018, Cancer.

Assessing patients’ risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?

G. Lyman, J. Crawford, E. Abella, 2015, Cancer medicine.

30 A risk model for first cycle neutropenic events in older cancer patients receiving systemic chemotherapy

G. Lyman, J. Crawford, D. Dale, 2006 .

Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium.

M. Socinski, R. Clough, M. Anscher, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Maintenance Sunitinib following Initial Platinum‐Based Combination Chemotherapy in Advanced‐Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double‐Blind, Placebo‐Controlled Phase III Study—CALGB 30607 (Alliance)

M. Socinski, P. Novotny, M. Edelman, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer.

J. Herndon, J. Crawford, M. Kelley, 2006, Lung cancer.

Treatment strategies for myeloid growth factors and intravenous iron: when, what, and how?

J. Crawford, G. Rodgers, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Use of Erythropoiesis-stimulating Agents (ESAs) in Lung Cancer Patients: Study-level and Patient-level Meta-analyses of Safety Outcomes

J. Crawford, H. Ludwig, K. Bridges, 2010 .

Dose Intensity and Hematologic Toxicity in Older Cancer Patients Receiving Systemic Chemotherapy.

G. Lyman, J. Crawford, D. Dale, 2005 .

Update: vinorelbine (navelbine) in non-small cell lung cancer.

J. Crawford, 1996, Seminars in oncology.

Comparison of Demographic Characteristics, Surgical Resection Patterns, and Survival Outcomes for Veterans and Nonveterans with Non-small Cell Lung Cancer in the Pacific Northwest

G. Lyman, J. Crawford, D. Au, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

OA 14.07 Progress in Lung Squamous Cell Carcinoma from the Lung-MAP Master Protocol (S1400) Sub-Studies S1400A, S1400B, S1400C and S1400D

M. Socinski, J. Engelman, R. Herbst, 2017 .

Optimal dosing of ABX-EGF in cancer patients

R. Figlin, A. Belldegrun, J. Crawford, 2002 .

Changing Patterns of Chemotherapy Delivery and Supportive Care for Aggressive B-Cell Non-Hodgkin's Lymphoma

G. Lyman, J. Crawford, D. Dale, 2011 .

Addressing unmet needs for people with cancer cachexia: recommendations from a multistakeholder workshop

T. Zimmers, Lisa Martin, J. Crawford, 2022, Journal of cachexia, sarcopenia and muscle.

A prediction model for chemotherapy-associated thrombocytopenia in cancer patients.

C. Francis, G. Lyman, J. Crawford, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictors of chemotherapy-induced neutropenia and its complications: results from a prospective nationwide registry.

G. Lyman, J. Crawford, D. Dale, 2005, The journal of supportive oncology.

Safety of concomitant use of granulocyte colony‐stimulating factor or granulocyte‐macrophage colony‐stimulating factor with cytotoxic chemotherapy agents

J. Crawford, William P. Petros, 1997, Current opinion in hematology.

Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and gemcitabine/cisplatin (GC) for the treatment of advanced solid malignancies.

J. Crawford, J. Gilbert, J. Stephenson, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Conditional Risk Model for Chemotherapy-Induced Anemia (CIA) in Cancer Patients.

G. Lyman, J. Crawford, D. Dale, 2007 .

A Phase II Trial of Denileukin Diftitox in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

J. Hainsworth, J. Crawford, R. Shukla, 2009, American journal of clinical oncology.

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).

J. S. Lee, D. R. Berry, G. Giaccone, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non‐small cell lung cancer

J. Herndon, J. Crawford, K. Leopold, 1994, Cancer.

EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.

N. Kearney, G. Lyman, M. Aapro, 2006, European journal of cancer.

Gene therapy for lung cancer.

J. Crawford, T. D’amico, H. Lyerly, 2000, Clinical lung cancer.

Using the MD Anderson Symptom Inventory (MDASI) to assess symptom burden and interference: Interim results of an open-label study of darbepoetin Alfa 200 mcg every 2 weeks (Q2W) for the treatment of chemotherapy-induced anemia (CIA)

D. Lubeck, C. Cleeland, J. Crawford, 2004 .

The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy.

G. Lyman, J. Crawford, P. K. Morrow, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Role of dietary carbohydrates on risk of lung cancer.

J. Crawford, H. Pang, A. Jatoi, 2021, Lung cancer.

Hematopoietic growth factors: ESMO recommendations for the applications.

J. Crawford, F. Roila, C. Caserta, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

G. Lyman, J. Crawford, D. Dale, 2008 .

Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia.

J. Crawford, H. Ludwig, K. Bridges, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preventing Obesity and Its Consequences

Arleen F. Brown, Ariane L. Bedimo-Rung, P. Shekelle, 2011 .

Hematopoietic growth factors: ESMO recommendations for the applications.

R. Greil, J. Crawford, F. Roila, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Highlights from: The 41st Annual Meeting of the American Society of Clinical Oncology; Orlando, FL.

J. Crawford, G. Reddy, V. Jain, 2005, Supportive cancer therapy.

Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data

L. Collette, M. Parmar, T. Eisen, 2013, The Lancet. Oncology.

Comparison of Demographic Characteristics, Surgical Resection Patterns, and Survival Outcomes for Veterans and Nonveterans with Non-small Cell Lung Cancer in the Pacific Northwest

G. Lyman, J. Crawford, D. Au, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Patterns of failure following combined modality therapy for esophageal cancer, 1984-1990.

B. Kavanagh, R. Dodge, G. Montana, 1992, International journal of radiation oncology, biology, physics.

Patterns of failure following combined modality therapy for esophageal cancer: The Duke University experience, 1984–1990

M. Anscher, J. Crawford, K. Leopold, 1991 .

Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants.

John D. Roberts, C. Bloomfield, N. Christakis, 2005, Journal of the National Cancer Institute.

Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy

G. Lyman, J. Crawford, D. Dale, 2011, Cancer.

New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.

J. Crawford, 2003, Journal of the National Comprehensive Cancer Network : JNCCN.

Characterizing the Clinical Relevance of an Embryonic Stem Cell Phenotype in Lung Adenocarcinoma

A. Potti, C. Acharya, K. Walters, 2009, Clinical Cancer Research.